apremilast + etanercept

This is a combination therapy consisting of apremilast and etanercept, two drugs with distinct mechanisms of action used primarily in the management of chronic inflammatory conditions such as plaque psoriasis and psoriatic arthritis. Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), which increases intracellular cAMP levels, leading to downregulation of pro-inflammatory cytokines (including TNF-α, IL-17, IL-23) and upregulation of anti-inflammatory mediators like IL-10[2][6][8][10]. Etanercept is a biologic fusion protein that acts as a tumor necrosis factor (TNF) inhibitor by binding to TNF molecules and preventing their interaction with cell surface receptors, thereby reducing inflammation[5]. While both agents are approved individually for similar indications, their concurrent use may be considered in select cases where monotherapy is insufficient; however, this combination should be used cautiously due to potential immunosuppressive effects and increased risk for infections[3][4][9].